Hepatitis B Vaccines Market By Dosage (Injectable Hepatitis B Vaccine, Oral Hepatitis B Vaccines), By Type Of Vaccine (Combined Vaccine, Single Antigen), By Final User (Government Supplies, Retailers And Pharmacies), By Channel Of Distribution (Public Sector Distribution, Distribution In Private Sec

Hepatitis B Vaccines Market Valuation – 2024-2031

The hepatitis B vaccine market is rapidly expanding due to several factors. Rising government initiatives, policies, and awareness programs have significantly promoted hepatitis B vaccination. The market size surpass USD 8.26 Billion valued in 2023 to reach a valuation of around USD 13.31 Billion by 2031.

The increasing number of hepatitis B infections and deaths has led various governments to implement strategies to boost vaccine coverage, including mandating hepatitis B vaccination for infants, children, and high-risk populations. The rising demand for cost-effective and efficient hepatitis B vaccines is enabling the market grow at a CAGR of 4.6% from 2024 to 2031.

Hepatitis B Vaccines MarketDefinition/ Overview

The Hepatitis B vaccine is a preventative measure that provides immunity against the hepatitis B virus (HBV). It works by stimulating the immune system to produce antibodies against the hepatitis B surface antigen (HBsAg), a protein present on the virus’s surface.

The vaccine is usually administered via intramuscular injection and can be given either as a single antigen vaccine or as part of combination vaccines that protect against multiple diseases. It is recommended for infants, children, adolescents, and adults at risk of HBV infection, and is a standard component of immunization programs in many countries.

Hepatitis B virus (HBV) represents a major global public health challenge and is a leading cause of cirrhosis, chronic hepatitis, and hepatocellular carcinoma. The increase in hepatitis B cases is primarily due to perinatal transmission, where newborns are infected during birth or through contact with the bodily fluids (such as blood or saliva) of an infected person.

How Will Initiatives for Global Immunisation Driving the Hepatitis B Vaccines Market?

The demand for Hepatitis B vaccinations is significantly driven by ongoing initiatives from international organizations and governments aimed at increasing vaccination rates as part of global immunization campaigns.

Organizations such as the World Health Organization (WHO), the United Nations Children’s Fund (UNICEF), and the Global Alliance for Vaccines and Immunization (GAVI) actively work to enhance vaccine accessibility and coverage worldwide.

These efforts include providing financial support, logistical assistance, and educational programs to raise awareness about the importance of Hepatitis B vaccination. Governments across various countries also contribute by implementing national vaccination programs, integrating Hepatitis B vaccination into routine immunization schedules, and conducting outreach campaigns to educate communities.

Such comprehensive strategies ensure higher vaccination rates, ultimately reducing the global burden of Hepatitis B and preventing related health complications.

How Cold Chain Logistics is Hampering the Hepatitis B Vaccines Market?

Cold chain storage and transportation are often essential for Hepatitis B vaccines, presenting significant logistical challenges in regions lacking adequate refrigeration infrastructure. Maintaining the cold chain is crucial to preserving the vaccine’s efficacy, as it requires consistent temperature control from production to administration.

In areas without reliable electricity or refrigeration facilities, ensuring proper storage and transport becomes difficult. This challenge is compounded in remote or rural locations where transportation infrastructure may be underdeveloped, further complicating the distribution process.

To address these issues, innovative solutions such as solar-powered refrigerators, portable cooling devices, and temperature monitoring technologies are being explored. Additionally, international aid and public-private partnerships are crucial in providing the necessary resources and support to strengthen cold chain systems in underserved regions.

Despite these efforts, the logistical hurdles remain a significant barrier to achieving widespread Hepatitis B vaccination coverage globally.

Category-Wise Acumens

How Combination Vaccines Has Become the Most Demanded in the Hepatitis B Vaccine Market?

The market for Hepatitis B vaccines is segmented by type into single antigen and combination vaccines. The combination segment held the largest market share. This dominance is attributed to several potential advantages over single antigen vaccines.

Combination vaccines offer improved cost-effectiveness and immunogenicity, providing protection against five or more diseases, including Hepatitis B, in a single formulation. This multifaceted protection reduces the need for multiple injections, which can improve patient compliance and convenience.

Additionally, combination vaccines often require administering only one or two doses, facilitating earlier protection against diseases compared to single antigen vaccines. These benefits make combination vaccines more appealing to healthcare providers and the public, driving their increased adoption and contributing to their substantial market share. As a result, the growing preference for combination vaccines has driven substantial growth in the Hepatitis B vaccine market.

How Government Supplies of Vaccines Driving the Growth of Hepatitis B Vaccines Market?

The government suppliers’ segment is projected to experience a significant CAGR during the forecast period. This robust growth is primarily driven by strategic initiatives from government bodies, including the the Pan American Health Organization, and national entities such as the Ministry of Health and Family Welfare. These organizations are dedicated to eradicating hepatitis B infection globally by launching national and international health programs that provide free immunization services.

These initiatives have led to an increased procurement of vaccines from major pharmaceutical companies, ensuring a steady and ample supply to meet the immunization needs of the population.

By focusing on large-scale vaccination campaigns, these programs aim to achieve widespread coverage and early disease protection, particularly in high-risk and underserved areas. The commitment to free-of-cost vaccination helps to remove financial barriers, encouraging higher participation rates in immunization programs.

As a result, these efforts are expected to significantly boost the growth of the government suppliers segment, as they play a crucial role in enhancing vaccine accessibility and reducing the global burden of hepatitis B.

Gain Access into Hepatitis B Vaccines Market Report Methodology

Country/Region-wise Acumens

How North America has become the Dominant Region in terms of the Hepatitis B vaccine Market?

North America is projected to maintain approximately 39.4% of the total market share throughout the forecast period. This market expansion is driven by the rising incidence of hepatitis B infections and an expanding at-risk population, including newborns and healthcare professionals.

Increased R&D investments aimed at enhancing vaccine efficacy and reducing the number of required doses is expected to significantly propel market growth. Additionally, government initiatives promoting vaccination and educational campaigns to increase vaccine coverage rates are anticipated to considerably boost the market value in the North American region.

For instance, previous Hepatitis B immunization recommendations based on individual risk factors were often stigmatizing, ineffective, and burdensome for both physicians and patients. Currently, only 30% of people in the United States are vaccinated against hepatitis B. Over the past decade, acute hepatitis B rates in the United States have steadily increased, particularly among individuals aged 40 and older. The critical role of universal vaccination campaigns in reducing viral morbidity is widely recognized, underscoring the importance of these efforts in curbing the spread of hepatitis B.

Will the increasing prevalence Fuelling the Asia Pacific region for the Hepatitis B Vaccines Market?

The Asia Pacific region is driving the expansion of the hepatitis B vaccine market. The high incidence rates, combined with increased knowledge of the disease and its severe health consequences, are driving more widespread vaccination initiatives. Governments and health organizations in the area are prioritizing hepatitis B vaccination campaigns, especially in countries with high infection rates such as China, India, and Southeast Asia. These activities, combined with advances in vaccine technology and improved healthcare infrastructure, are helping to grow the market for hepatitis B vaccines throughout the Asia Pacific.

According to the India has the world’s second-biggest burden of chronic HBV infections. In India, approximately 50 million persons are chronic HBV carriers, with hepatitis B surface antigen (HBsAg)1 prevalence ranging from 2 to 8% in the general population. India falls to the “intermediate to high endemicity” group of nations for hepatitis B surface antigen, accounting for approximately 11% of the estimated worldwide burden. Every year, around 115, 000 Indians die from HBV infections and sequelae. Children in India are more vulnerable to infection due to insufficient cleanliness and high population density.

Competitive Landscape

The hepatitis B vaccine market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the hepatitis B vaccine market include

Merck & Co., Inc., GlaxoSmithKline plc., Sanofi Pasteur, Walgreens Boots Alliance, Inc., Serum Institute of India Pvt. Ltd., China National Biotech Group Co., Ltd., F. Hoffmann-La Roche Ltd., Mylan N.V., Shionogi & Co., Ltd., Abbott Laboratories.

Latest Developments

• In August 2021, Sanofi acquired Translate Bio, Inc. This strategic acquisition aimed to leverage mRNA technology for the development of vaccines and therapeutics, helping Sanofi maintain long-term business relationships and expand into untapped markets.
• In June 2021, Merck and Sanofi launched Vaxelis, the first and only six-in-one paediatric combination vaccine in the U.S. market. Vaxelis is designed for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease caused by Haemophilus influenzae type B. This strategy enabled the companies to strengthen their revenue streams and consolidate their market positions.

Report Scope

Hepatitis B Vaccine Market, By Category

Dosage

• Injectable Hepatitis B Vaccine
• Oral Hepatitis B Vaccines

Type Of Vaccine

• Combined Vaccine
• Single Antigen

Final User

• Hospitals And Clinics
• Retailers And pharmacies
• Government Supplies
• Travel Clinics

Channel Of Distribution

• Public Sector Distribution
• Distribution In The Private Sector

Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players• The current as well as future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post sales analyst support

Customization of the Report

In case of any please connect with our sales team, who will ensure that your requirements are met.